Clinical trials in multiple sclerosis - The importance of the outcome measure

被引：0
|
作者：
Zajicek, J
Thompson, A
Hobart, J
机构：
[1] Peninsula Med Sch, Plymouth, Devon, England
[2] Derriford Hosp, Plymouth PL6 8DH, Devon, England
[3] UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2004年 / 75卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
013
引用
收藏
页码：1215 / 1215
页数：1
相关论文
共 50 条
  • [21] Cutting the cost and length of clinical trials - the importance of choosing the right outcome measure
    Zajicek, J
    Thompson, A
    Hobart, J
    JOURNAL OF NEUROLOGY, 2004, 251 : 152 - 153
  • [22] Imaging as an Outcome Measure in Multiple Sclerosis
    Daniel Ontaneda
    Robert J. Fox
    Neurotherapeutics, 2017, 14 : 24 - 34
  • [23] Imaging as an Outcome Measure in Multiple Sclerosis
    Ontaneda, Daniel
    Fox, Robert J.
    NEUROTHERAPEUTICS, 2017, 14 (01) : 24 - 34
  • [24] Development of a multiple sclerosis functional composite as a clinical trial outcome measure
    Cutter, GR
    Baier, ML
    Rudick, RA
    Cookfair, DL
    Fischer, JS
    Petkau, J
    Syndulko, K
    Weinshenker, BG
    Antel, JP
    Confavreux, C
    Ellison, GW
    Lublin, F
    Miller, AE
    Rao, SM
    Reingold, S
    Thompson, A
    Willoughby, E
    BRAIN, 1999, 122 : 871 - 882
  • [25] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
    Bernard M. J. Uitdehaag
    CNS Drugs, 2018, 32 : 543 - 558
  • [26] OUTCOME MEASURES FOR CLINICAL-TRIALS IN MULTIPLE-SCLEROSIS - REPLY
    MCFARLAND, HF
    ANNALS OF NEUROLOGY, 1992, 31 (01) : 116 - 117
  • [27] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
    Uitdehaag, Bernard M. J.
    CNS DRUGS, 2018, 32 (06) : 543 - 558
  • [28] Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis
    Koch, Marcus W.
    Mostert, Jop
    Repovic, Pavle
    Bowen, James D.
    Uitdehaag, Bernard
    Cutter, Gary
    NEUROLOGY, 2021, 96 (01) : E111 - E120
  • [29] Appropriate design and outcome measures in multiple sclerosis clinical trials - Response
    Khan, OA
    Tselis, AC
    Kamholz, JA
    Garbern, JY
    Lewis, RA
    Lisak, RP
    EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (05) : 505 - 506
  • [30] Measuring fatigue in multiple sclerosis clinical trials: why patient reported outcome measure choice is not immaterial when measuring change
    Hobart, Jeremy
    King, Tanya
    Sappl, Sonia
    Marais, Ida
    Close, James
    Vo, Pamela
    Andrich, David
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 450 - 451
12345